The study highlights poor outcomes for leukaemia patients with a history of myelodysplastic syndrome treatment and related ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

Researchers sought to determine whether venetoclax plus decitabine would lead to enhanced feasibility for allogeneic HSCT in patients with AML.

Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.

acute myeloid leukemia (AML). "Some people call it AML -- I like to make the distinction and call it accelerated or a blast-phase MPN, because it does behave a little bit differently than just ...

Dr. Soheil Meshinchi is an expert in leukemia biology, peripheral blood stem cell transplantation for children with leukemia, management of post-transplant relapse and targeted therapies for acute ...